About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Current Search
Report Type
Organization
Disposition
Year
Month
Found 6532 record(s)
Req # A-2023-001473
Adverse Drug Reactions (ADRs). Report numbers: E2B_ 06770551, E2B_06787144.Organization: Health Canada
July 2024
Req # A-2023-001522
Adverse Drug Reaction (ADR). Report number: E2B_05173067.Organization: Health Canada
July 2024
Req # A-2023-001534
Adverse Drug Reactions (ADRs). Report numbers: 001067388, E2B_06778630, 001066676, 001067290, 001071749, 001071491, E2B_06785278, E2B_06800937.Organization: Health Canada
July 2024
Req # A-2023-001562
Adverse Drug Reactions (ADRs). Report numbers: 001070183, 001070713.Organization: Health Canada
July 2024
Req # A-2023-001575
Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 23-111864-298.Organization: Health Canada
July 2024
Req # A-2023-001615
Adverse Drug Reactions (ADRs). Report numbers: 001069121, E2B_06818695, E2B_06772717.Organization: Health Canada
July 2024
Req # A-2023-001622
Adverse Drug Reactions (ADRs) for Mesalimine. Report numbers: E2B_06850804, E2B_06862609. ADRs for CUVITRU. Report numbers: E2B_06897676, E2B_06897774, E2B_06897655, E2B_06897714, E2B_06897705, E2B_06897712, E2B_06897664, E2B_06897688.Organization: Health Canada
July 2024
Req # A-2023-001625
Adverse Drug Reactions (ADRs) for Mesalazine. Report numbers: E2B_06860106, E2B_06879090, E2B_06897644. ADRs for Immunoglobulin (human). Report numbers: E2B_06848171, 001069979, 001069986, E2B_06894900, E2B_06839700, E2B_06886486, 001069997.Organization: Health Canada
July 2024
Req # A-2023-001631
Adverse Drug Reaction (ADR). Report number: 001069831.Organization: Health Canada
July 2024
Req # A-2024-000016
Adverse Drug Reaction (ADR) for EMTRICITABINE/TENOFOVIR. Report number: E2B_06027461.Organization: Health Canada
July 2024